NEW YORK (GenomeWeb News) – A team led by researchers at Columbia University Medical Center uncovered a new gene linked with pulmonary arterial hypertension, and as the group reported in The New England Journal of Medicine
EGEN announced this week that its microRNA inhibitor-based treatment for pulmonary arterial hypertension was able to reverse the pulmonary hypertension associated with advanced stages of the disease and restore cardiovascular function in rat models.
Miragen Therapeutics said this week that it has taken an exclusive license to intellectual property held by the University of Glasgow that is related to the use of microRNA-145 in the treatment of pulmonary arterial hypertension.
Terms of the deal were not disclosed.
The awards are part of NHLBI's newest proteomics program, which seeks to "understand the mechanisms that underlie many of the clinical questions related to heart, lung, and blood disease," said an official.
Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.